[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-pulmonary-nodules\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-pulmonary-nodules":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,76,91,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100651962","multiparametric-lung-mri-with-diffusion-weighted-imaging-in-lung-rads-4-lesion-characterization-100651962",false,"NCT07768046","Multiparametric Lung MRI With Diffusion-Weighted Imaging in Lung-RADS 4 Lesion Characterization","Multiparametric Lung MRI With Diffusion-Weighted Imaging in Lung-RADS 4 Lesion Characterization: A Single-Center Prospective Diagnostic Accuracy Study","Inclusion Criteria:\n\n1. Age 50 to 80 years, inclusive.\n2. At least a 20 pack-year cigarette smoking history, and currently smoking or quit within the past 15 years (2021 USPSTF lung cancer screening eligibility).\n3. Underwent a standard-of-care lung cancer screening low-dose chest CT (LDCT) at the University of Florida that was assigned Lung-RADS category 4 (4A, 4B, or 4X) per ACR Lung-RADS v2022.\n4. Able to provide written informed consent independently.\n\nExclusion Criteria:\n\n1. Part-solid or cystic nodule with a solid component measuring less than 8 mm.\n2. Endobronchial nodule.\n3. MRI-incompatible or potentially MRI-incompatible implanted device.\n4. Claustrophobia that would prevent the participant from tolerating the MRI examination.\n5. Metallic device in the chest wall or spine that may interfere with adequate image acquisition in the field of view (assessed case by case).\n6. History of prior lung resection for a benign condition that may create susceptibility artifact in the field of view.\n7. Home oxygen supplementation.\n8. Active or treated lower respiratory tract infection within the prior 4 weeks.\n9. Lack of capacity to consent.","ALL","50 Years","80 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","This study evaluates whether multiparametric chest magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI), performed without any contrast material, can distinguish malignant from benign lung lesions that were assigned Lung-RADS category 4 on a standard-of-care lung cancer screening low-dose CT.\n\nParticipants who have a Lung-RADS 4 lesion on screening CT undergo one non-contrast research MRI of the chest at 3.0 Tesla. The MRI is added to standard care; no standard-of-care imaging, biopsy, or treatment is withheld or replaced, and the research MRI is not used for clinical decision making. Participants then continue routine clinical management, and the final nature of the lesion is established from pathology or microbiology when tissue is obtained, or otherwise from at least 24 months of clinical and imaging follow-up.\n\nThe primary measure is the sensitivity and specificity of multiparametric MRI against that final diagnosis. Secondary measures include whether DWI alone performs as well as the full MRI protocol, how MRI compares with PET\u002FCT in participants who had PET\u002FCT as part of their care, and quantitative MRI thresholds (apparent diffusion coefficient, lesion-to-spinal-cord signal intensity ratio, native T1 and T2).\n\nThis is an exploratory pilot and feasibility study. No formal power calculation was performed; the sample size is intended to support feasibility assessment, protocol optimization, and preliminary estimates of diagnostic performance.",[25,26,27,28],"Solitary Pulmonary Nodule","Multiple Pulmonary Nodules","Lung Neoplasms","Lung Cancer Screening",[30,31,32,33,34,35,36,37,38],"Lung-RADS 4","diffusion-weighted imaging","apparent diffusion coefficient","multiparametric MRI","lung cancer screening","low-dose CT","pulmonary nodule","diagnostic accuracy","non-contrast MRI","NOT_YET_RECRUITING","2026-08-17",{"date":42,"type":43},"2026-08-19","ACTUAL",{"date":45,"type":21},"2027-01",{"date":47,"type":21},"2032-01",{"name":49,"class":50},"University of Florida","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":22,"phases":4,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100642338","peripheral-blood-cytof-and-viral-imprinting-in-postoperative-multiple-pulmonary-nodules-100642338","NCT07647484","Peripheral Blood CyTOF and Viral Imprinting in Postoperative Multiple Pulmonary Nodules","A Multicenter Prospective Cohort Study of Peripheral Blood CyTOF Immune Phenotyping and Viral Imprinting in Patients With Postoperative Multiple Pulmonary Nodules","Inclusion Criteria:\n\nAge 18 years or older, any sex. Primary pulmonary nodule has been surgically resected, with residual multiple pulmonary nodules or a need for pulmonary nodule-related routine postoperative follow-up.\n\nPlanned routine postoperative follow-up at a participating center and able to provide a research blood sample together with routine blood draw when clinically available.\n\nAble to understand the study and willing to provide written informed consent before research blood sample collection.\n\nExclusion Criteria:\n\nInvestigator judges that the participant is unsuitable for additional small-volume blood collection, such as severe anemia, obvious coagulation abnormality, recent severe bleeding, or high risk of severe vasovagal reaction.\n\nAcute severe infection, acute major organ dysfunction, or other condition that may substantially affect peripheral immune status and makes study participation unsuitable.\n\nCurrent strong immunosuppressive therapy that may substantially affect peripheral immune status and cannot be adequately recorded or adjusted for in analysis.\n\nUnable to complete informed consent or explicitly refuses use of research blood samples and related data for this study.\n\nAny other condition that, in the investigator's judgment, makes participation inappropriate.","18 Years",{"count":61,"type":21},200,"200 Months","This multicenter prospective cohort study will enroll adults who have undergone resection of a primary pulmonary nodule and have residual multiple pulmonary nodules or require routine postoperative pulmonary nodule follow-up. During clinically indicated follow-up visits, a small amount of peripheral venous blood will be collected at the same time as routine blood draws for research CyTOF immune phenotyping and viral imprinting-related serology. The study will not assign participants to treatment, change follow-up schedules, imaging, medication, surgery, or other clinical care. Research laboratory results will not be returned to participants or entered into medical records. The study will describe longitudinal peripheral immune-cell profiles and explore associations among T\u002FB\u002FNK cell phenotypes, T-cell differentiation and senescence\u002Fexhaustion markers, viral imprinting markers, and postoperative residual or new pulmonary nodule evolution.",[26],[66],"CyTOF","2026-06-12",{"date":69,"type":43},"2026-06-15",{"date":71,"type":21},"2026-07",{"date":73,"type":21},"2028-12",{"name":75,"class":50},"The First Affiliated Hospital of Guangzhou Medical University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":63,"conditions":84,"keywords":85,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":90,"locationsCount":4},"100642174","single-center-cytof-and-viral-imprinting-study-in-postoperative-multiple-pulmonary-nodules-100642174","NCT07647055","Single-Center CyTOF and Viral Imprinting Study in Postoperative Multiple Pulmonary Nodules","A Single-Center Prospective Cohort Study of Peripheral Blood CyTOF Immune Phenotyping and Viral Imprinting in Patients With Postoperative Multiple Pulmonary Nodules","Inclusion Criteria:\n\n* Age 18 years or older, any sex. Primary pulmonary nodule has been surgically resected, with residual multiple pulmonary nodules or a need for pulmonary nodule-related routine postoperative follow-up.\n\nPlanned routine postoperative follow-up at a participating center and able to provide a research blood sample together with routine blood draw when clinically available.\n\nAble to understand the study and willing to provide written informed consent before research blood sample collection.\n\nExclusion Criteria:\n\n* Investigator judges that the participant is unsuitable for additional small-volume blood collection, such as severe anemia, obvious coagulation abnormality, recent severe bleeding, or high risk of severe vasovagal reaction.\n\nAcute severe infection, acute major organ dysfunction, or other condition that may substantially affect peripheral immune status and makes study participation unsuitable.\n\nCurrent strong immunosuppressive therapy that may substantially affect peripheral immune status and cannot be adequately recorded or adjusted for in analysis.\n\nUnable to complete informed consent or explicitly refuses use of research blood samples and related data for this study.\n\nAny other condition that, in the investigator's judgment, makes participation inappropriate.",{"count":61,"type":21},[26],[66],"2026-06-09",{"date":69,"type":43},{"date":71,"type":21},{"date":73,"type":21},{"name":75,"class":50},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":51},"100623340","hybrid-robot-assisted-percutaneous-ablation-and-non-intubated-vats-for-multiple-pulmonary-nodules-100623340","NCT07395362","Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules","A Prospective Single-Arm Study Evaluating the Safety, Feasibility, and Perioperative Recovery of Robot-Assisted Percutaneous Ablation\u002FLocalization Combined With Non-Intubated Video-Assisted Thoracoscopic Surgery for Multiple Pulmonary Nodules","Inclusion Criteria:\n\n1. Age 18 to 85 years at the time of enrollment.\n2. Presence of multiple pulmonary nodules identified on chest computed tomography (CT).\n3. At least one dominant pulmonary lesion meeting standard indications for thoracoscopic surgical resection based on radiologic assessment.\n4. At least one additional pulmonary nodule for which complete surgical resection is considered undesirable due to lung parenchyma preservation concerns or procedural risk, and deemed suitable for robot-assisted CT-guided percutaneous intervention.\n5. Determined by a multidisciplinary team (MDT) to be an appropriate candidate for the predefined hybrid treatment strategy.\n6. Eligible for non-intubated video-assisted thoracoscopic surgery based on preoperative anesthetic evaluation (ASA physical status I-III).\n7. Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n1. Pulmonary nodules located centrally or adjacent to major airways, major vessels, or the heart, where safe percutaneous intervention is not feasible.\n2. Pure ground-glass nodules with a maximum diameter \\\u003C 6 mm, for which active surveillance is recommended.\n3. Clinical evidence of N1\u002FN2 lymph node involvement or distant metastasis.\n4. Severe cardiopulmonary disease, interstitial lung disease, or other conditions that preclude thoracoscopic surgery or anesthesia.\n5. Coagulation disorders or ongoing anticoagulation therapy that cannot be safely discontinued.\n6. Pregnancy or breastfeeding.\n7. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study assessments.","85 Years",{"count":20,"type":21},"INTERVENTIONAL",[102],"NA","The goal of this clinical trial is to evaluate the safety and feasibility of a predefined hybrid treatment strategy in patients with multiple pulmonary nodules who require surgical management of at least one dominant lesion. The strategy combines robot-assisted CT-guided percutaneous ablation and\u002For localization with non-intubated video-assisted thoracoscopic surgery (NiVATS) performed during the same hospitalization.\n\nThe main questions this study aims to answer are:\n\nIs the hybrid treatment strategy associated with an acceptable rate of perioperative serious complications?\n\nCan the planned combination of robot-assisted percutaneous intervention and NiVATS be completed successfully in a real-world clinical setting?\n\nParticipants will:\n\nUndergo preoperative evaluation and multidisciplinary assessment;\n\nReceive robot-assisted CT-guided percutaneous ablation and\u002For localization for selected pulmonary nodules;\n\nUndergo non-intubated video-assisted thoracoscopic surgery for resection of the dominant pulmonary lesion;\n\nBe followed for perioperative outcomes and short-term recovery up to 30 days after surgery.",[26],[106,107,108,109,110],"Multiple pulmonary nodules","Ground-glass nodules","Robot-assisted percutaneous ablation","CT-guided intervention","Non-intubated video-assisted thoracoscopic surgery NiVATS","2026-02-06",{"date":113,"type":43},"2026-02-09",{"date":115,"type":21},"2026-02-28",{"date":117,"type":21},"2026-10-01",{"name":75,"class":50},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":126,"targetDuration":128,"studyType":22,"phases":4,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":51},"100551329","a-prospective-non-interventional-cohort-study-of-subsolid-pulmonary-nodules-100551329","NCT06458673","A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules","Prediction of Growth Trend of Pulmonary Nodules Based on Multi-temporal and Multimodal Medical Data and Its Impact on Pulmonary Nodule Management Strategies","Inclusion Criteria:\n\n* Age≥ 18 years old, gender is not limited\n* Confirmed subsolid pulmonary nodule by CT, initial pulmonary nodule ≥ 5 mm (including subsolid components) and ≤ 30 mm, do not shrink or disappear after 3 months Follow-up.\n* ECOG 0～2\n* Able to provide CT in DICOM format\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Long-term use of immunosuppressants and hormone drugs\n* History of previous malignancy (if there is no recurrence or carcinoma in situ for more than 5 years after receiving curative therapy, it can be enrolled)\n* Inability to cooperate with regular follow-up\n* Poor general condition, with the life expectancy less than 6 months",{"count":127,"type":21},1184,"5 Years","Some studies have shown that the model for judging and predicting the growth of sub-solid pulmonary nodules through big data and deep learning can detect nodule growth earlier. Since most of the training data come from large foreign samples, most of the validated data are CT data from a single center or a few centers, and their generalization ability needs to be further verified. In order to better study subsolid pulmonary nodules in the lungs in China, we plan to conduct a prospective, multicenter, non-interventional observational cohort study.",[131,26],"Solitary Lung Nodule",[133,134,135],"Lung Nodule","Prospective","Observational Study","2024-11-27",{"date":138,"type":43},"2024-12-02",{"date":140,"type":21},"2024-12-01",{"date":142,"type":21},"2030-11-30",{"name":144,"class":50},"Guangdong Provincial People's Hospital"]